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ABSTRACT We have devised a strategy based on poly-
merase chain reaction (PCR) for the rapid cloning offunctional
antibody genes as single-chain immunotoxins. RNA from a
hybridoma producing an antibody (OVB3) that reacts with
ovarian cancer cells was used as a template to make the first
strand of a cDNA. Then a second strand was synthesized and
amplified by using two sets ofDNA primers that (t) hybridized
to the ends of the light- and heavy-chain variable regions, (iU)
encoded a linker peptide, and (uit) contained appropriate
restriction enzyme sites for cloning. After 30 cycles ofPCR, the
DNA fragments containing sequences encoding the light- and
heavy-chain variable regions were cloned into an Escherichia
coi expression vector containing a portion of the Pseudomonas
exotoxin gene. Clones encoding recombinant single-chain im-
munotoxins were expressed in E. coli and the protein product
was assessed for its ability to bind to or kill cells bearing the
OVB3 antigen. By using this approach it should be possible to
rapidly clone the functional variable region sequences of many
different antibodies from hybridoma RNA.
"Targeted toxins" represent a different approach to cytocidal
therapy (1, 2). For this purpose, protein toxins have been
chemically attached to monoclonal antibodies (mAbs) to make
immunotoxins (1, 2), or genes encoding toxins have been fused
to growth factor genes to create growth factor-toxin fusion
proteins (3). Recently, fragments of antibodies containing the
antigen binding site(s) have been produced in Escherichia coli
either as two chains or as single-chain antibodies (4-7). We
have produced a recombinant single-chain immunotoxin, anti-
Tac (Fv)-PE40, which consists of the variable domains of a
mAb directed at the interleukin 2 receptor linked to a modified
40 kDa form of Pseudomonas exotoxin (PE40) (8). To con-
struct single-chain immunotoxins, only the DNA sequences
encoding the variable domains of the light and heavy chains of
an antibody and that of a toxin are required.
Polymerase chain reaction (PCR) is now widely used for
genomic and cDNA cloning (9-11). Recently, PCR has been
used to amplify genes encoding variable domains of antibod-
ies (12-14). Here we describe a PCR-based method ofcloning
the variable light- and heavy-chain (VL and VH) genes of an
antibody directly from total RNA. The genes are expressed
in E. coli fused to PE as a functional single-chain immuno-
toxin. We have now used this method to clone the VL and VH
of mAb OVB3, an antibody that reacts with many human
ovarian cancers (15). This immunotoxin selectively kills
OVCAR3 cells, which express the OVB3 antigen.
METHODS
Identification of Rare Restriction Enzyme Recognition Sites
and Primers for Amplification. The nucleotide sequences
encoding VL and VH of murine antibody were extracted from
the Kabat's nucleotide data base (16) and subjected to the
computer program FPAT (Chuck Buckler, National Institutes
of Health, personal communication) to analyze the presence
of restriction enzyme recognition sites (see Table 1). Two
sets of two primers each were devised for the amplification
of the VL and VH of murine mAb OVB3 (see Fig. 1A). VL-5'
was based on the N-terminal amino acid sequence of the
OVB3 light chain and contained 23 nucleotides encoding the
N-terminal amino acids of the light chain and an Nde I site 5'
to these nucleotides. VL-3' contained a Sal I site, nucleotides
complementary to those encoding a linker peptide, and its 3'
end was complimentary to the joining (J) region of a mouse
K light chain. VH-5' contained a Sal I site and 20 nucleotides
encoding the N-terminal amino acids of the heavy chain.
VH-3' contained a HindIII site and its 3' end was comple-
mentary to the J region of the heavy chain.
RNA Isolation, cDNA Synthesis, and Amplification. RNA
was prepared from =5 x 107 hybridoma cells (17). Total RNA
was used for first strand cDNA synthesis using random
primers at 370C for 1 hr in a 200-,l reaction mixture contain-
ing 40 ,ug of total RNA, 6.6 ,l of RNase- and DNase-free
bovine serum albumin (3 ,ug/,l; Pharmacia), 4 Al of 25 mM
dNTPs, 4 Al of RNasin (40,000 units/Al; Promega), 120 ng of
random primer (New England Biolabs), 40 ,ul of 5 x reaction
buffer, and 20 ,ul of reverse transcriptase (Moloney murine
leukemia virus reverse transcriptase, 200 units/pl from
BRL). (The 5x reaction buffer = 250 mM Tris-HCl, pH
7.5/375 mM KCl/50 mM dithiothreitol/15 mM MgCl2.)
For amplification of VL and VH, 5 pl of cDNA was
subjected to 30 cycles of PCR using reagents as per the
manufacturer's instructions (Gene Amp; Perkin-Elmer/
Cetus) in two separate tubes with 1 ,uM each either VL-5' and
VL-3' or VH-5' and VH-3' primers. Each PCR cycle consisted
of denaturation at 94°C for 1 min, annealing at 55°C for 90 sec,
and polymerization at 72°C for 2 min with a 10-sec extension
in each cycle. The amplified VL and VH fragments were
purified on 2% low-melting-point agarose (SeaPlaque; FMC).
Cloning of Amplified Fragments into a Bacterial Expression
Vector. Plasmid pVC387 (18) was modified so that it con-
tained a HindIII site between transforming growth factor type
a and PE40. The purified PCR products were digested with
Nde I and Sal I for the fragment encoding VL and linker at its
3' end, or with Sal I and HindIII for VH (see Fig. 1B).
Expression vector pVC 38H was digested with Nde I and
HindIII and dephosphorylated with calf intestinal phospha-
tase. VL and VH fragments were purified on 1.8% SeaPlaque
agarose. The vector was separated on 1.2% SeaPlaque aga-
rose and a 3.6-kilobase (kb) fragment was isolated. A three-
fragment ligation was performed with the 3.6-kb vector, VL
and VH fragments. The recombinants were screened with
Abbreviations: PE, Pseudomonas exotoxin; PE40, 40-kDa PE; mAb,
monoclonal antibody; VH, heavy-chain variable region; VL, light-
chain variable region; PCR, polymerase chain reaction; J, joining.
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Xba I and Sal I. Several positive clones were always checked
for protein expression. To produce recombinant immuno-
toxin with a full-length PE clone pOVB3158-2 was digested
with Xba I and HindIII to isolate an 800-base-pair (bp)
fragment and ligated to a 4.9-kb fragment of Xba I/HindIll
digested, dephosphorylated pVC45 f+T (19).
Expression and Analyses. Plasmid DNA from several
clones of pOVB3-158 was transformed in BL21(ADE3) (20).
Transformant colonies were inoculated in 5 ml ofLB medium
containing ampicillin (100 pug/ml) and induced with 1 mM
isopropyl f-D-thiogalactopyranoside at an OD650 of -0.8.
After 90 min at 370C, 200 gl of the culture was saved for
SDS/PAGE. The rest was centrifuged and the pellet was
suspended in 1 ml of extraction buffer (7 M guanidine/100
mM Tris HCl, pH 8.0/5 mM EDTA), mixed in a Vortex, kept
on ice for 1 hr, and then spun at 12,000 rpm in a microcen-
trifuge. Five hundred microtiters of the guanidine extract
containing proteins was diluted in 10 ml of rapidly stirred
phosphate-buffered saline (PBS) and was allowed to stand
overnight. A sample was dialyzed against 20 mM Tris HCI
(pH 7.4) in a microdialyzer unit (BRL), centrifuged at 12,000
rpm for 10 min, and tested for ADP ribosylation activity and
binding to OVCAR-3 cells by an immunofluorescence assay.
OVB3 (Fv)-PE was expressed from plasmid pOVB3154-2.
The protein was extracted from the inclusion bodies as
described (21, 22) and was further purified on a Mono Q and
a TSK-250 column.
Binding, Cytotoxicity, and Other Analytical Assays of Re-
combinant Proteins. Binding of chimeric toxins to OVCAR3
cells was evaluated by immunofluorescence. Proteins were
diluted in Dulbecco's PBS containing 0.2% bovine serum
albumin and incubated with OVCAR3 cells at 4°C for 1 hr,
followed by a polyclonal rabbit antibody to PE and rhoda-
mine-conjtigated affinity-purified goat anti-rabbit IgG. The
cells were fixed and viewed in a fluorescence microscope.
ADP ribosylation assays were performed as described (21,
22). Cytotoxicity on human ovarian carcinoma cell line
OVCAR3, murine Swiss 3T3 cells, and human leukemia T
cells (HUT 102) was determined by assaying inhibition of
protein synthesis (19, 21). SDS/PAGE was performed on
10% gels and immunoblotting was performed with polyclonal
rabbit antibodies to PE (21). N-terminal amino acid sequenc-
ing of light and heavy chains of OVB3 was performed after
their separation on SDS/polyacrylamide gel and transblot-
ting onto Immobilon membranes (Millipore).
RESULTS
Identification of Rare Restriction Enzyme Sites and Primer
Selection. To synthesize a cDNA encoding antibody genes,
the restriction sites used for cloning the antibody genes
cannot also be present in the variable region DNA sequences
to be cloned. Therefore, a computer search of Kabat's
nucleotide data base (16) was carried out to identify rare
restriction sites in the genes encoding the murine VL and VH
and enzyme sites that were either absent or rarely present
were identified (Table 1). Because of the expression vector
we used, Nde I and HindIII, which are rarely found in
antibody genes, were chosen as cloning sites. In addition,
restriction enzyme site Sal I was introduced at the 3' end of
the linker in VL and at the 5' end of VH (Table 1 and Fig. 1A).
The sequences of the 5' primers for both VL and VH were
based on the N-terminal amino acid sequence of the light and
heavy chain of OVB3, respectively (Fig. 1A). In general,
primers were designed so that 23 nucleotides at the 3' end of
the primers would not have more than two to five mis-
matches. These mismatches occur because of variations in
the N-terminal and J-region sequences and the degenerate
nature of the codons. The base at the 3' end of each primer
was either the first or second base of a codon or comple-
Table 1. Frequency of restriction enzyme recognition sites in the
variable domains of mouse immunoglobulins
Frequency
Restriction Light Heavy Restriction
site chain* chaint site
Aat I 0 1 HindIII
Afl II 0 1 Hpa I
Ava III 5 0 Kpn I
Apa I 0 0 Mlu I
ApaLI 1 1 Nar I
Ase I 9 16 Nco I
BamHI 12 3 Nde I
Bcl I 1 1 Nhe I
BglII 0 3 NotI
BstBI 0 0 Nru I
BspHI 0 2 PflMI
BstEII 6 13 Pst I
BstXI 19 3 Pvu II
Bsu36I 2 8 Sac I
Drd I ND 33 Sac II
Cla I 0 0 Sal I
EagI 0 0 SmiaI
EcoRI 0 6 Spl I
EcoRV 0 7 Xba I
Esp I 0 32 Xho I
Frequency
Light Heavy
chain* chaint
1 3
0 0
17 2
0 2
0 8
ND 10
2 1
0 0
ND 0
0 0
13 0
29 46
0 35
0 5
0 1
0 0
0 0
2 0
ND 0
ND 0
ND, not determined.
*Fifty sequences from Kabat's data base were analyzed.
tOne hundred sequences from Kabat's data base were analyzed.
mentary to the same. This was necessary because polymer-
ization could only occur if the last base ofthe primer annealed
to the template.
Amplification, Cloning, and Expression of Variable Do-
mains. After first-strand synthesis, the cDNA was subjected
to a 30-cycle PCR in two separate reactions. One reaction
mixture contained primers VL-5' and VL-3' for amplifying
VL, while the other contained VH-5' and VH-3' for amplifying
VH. After amplification both reaction tubes showed a major
band of =350 bp (data not shown). VL and VH were cloned
into an expression vector containing a modified form of PE
as shown in Fig. 1B. Analyses of recombinant clones re-
vealed that 70o of the clones contain VL, VH, and PE40 (data
not shown). Upon expression in BL21 (ADE3), 80% of these
recombinants expressed a fusion protein ofthe expected size,
as detected on SDS/polyacrylamide gel by Coomassie blue
staining and immunoblotting using antibodies to PE (data not
shown). Overall, 50% of the clones appeared to be correct
because they expressed an immunoreactive protein of the
expected size (63 kDa). The fusion protein bound to
OVCAR3 cells when examined by immunofluorescence (Fig.
2A). Also, intact OVB3 competed for the binding (Fig. 2B).
Two of the clones pOVB3 158-1 and pOVB3 158-2 were
sequenced (Fig. 3). Both the clones had identical coding
sequences, indicating that no major changes in sequence
were produced in the PCR reaction. However, pOVB3 158-2
did not have an Nde I site; it was missing a C residue of the
Nde I restriction site, which did not affect expression of the
fusion protein.
These two fusion proteins were minimally toxic to OVCAR3
cells, which was not surprising since chemical conjugates of
OVB3 and PE40 have low cytotoxicity toward OVCAR3 cells,
and conjugates offull-length PE with OVB3 are very cytotoxic
(23). Therefore, we replaced the PE40 portion ofpOVB3158-2
with full-length PE to create pOVB3 154-2 (Fig. 1B). Upon its
expression, protein of the expected size (89 kDa) was pro-
duced (Fig. 4, lane A). OVB3 (Fv)-PE was purified from
inclusion bodies (22, 23) by guanidine denaturation and Mono
Q and TSK-250 chromatography (lanes B and C). Purified
Immunology: Chaudhary et al.
1068 Immunology: Chaudhary et al.
A
VL-5' 5'
VL-3' 5'
Ve-51 5'
VH-31 51
3,
3'
'ATTTTAAARGGTGTCGTCGACGATGTGCAGCTGGTGGAGTCTGG 3,
'AGACTGITGGGGGTGTTGAAGCTTTTGAGG GkCTGTGAGAGTGGTTCC 3,
B RNA
(i) Annealing with Random Primers
(ii) Reverse Transcriptase
cDNA (First strand)
VL- 5 VH- 5'
VL- PCR H-
N s S H
NdeI Sal
Sal I Hind III
N S S H
I Ligase x Hg
XN S H S B EiLE409 ~~~~~~~~~~~~~~~~~~~.............':'
pOVB3 158i~~~~~~ Xb Amp-E
Xba
Hind III
XN S H
l I
ML/AM
Ligase
Linker
GluGlyLysSerSerGlySerGlySerGIuSerLysValAsp
XN HS S B E
VE at_L PE
pOVB3 154-2 f+T
.. .. __ . _ _Amp
X N H S B E
pVC 38H
Ncle
Hind
1Alkaline Phosphatase
XN H B E
,
,. ..
S B E
pVC45 f+T
Xba
Hind IlI
Alkaline Phosphatase
X HSS B E
I..
L~~ ~~ ...... . .......
Variable Domain of theVL Light Chain
Variable Domain of the1~Heavy Chain
Peptide Linker
3 Transforming Growth Factor
W Tra nslocation and
ADPribosylation Domains of PE
Binding Domein of PE
row_ Outer Membrane Prote r. AW22 Signat Sequence
FIG. 1. (A) Primers for am-
plification using PCR. VL-5' and
VH-5' hybridize to the antisense
strand in the 5' region of se-
quences encoding the mature
light and heavy chains, respec-
tively. VL-3' and VH-3' hybrid-
ize to the sense strand in the J
region of the light and heavy
chains, respectively. The re-
striction sites, introduced for
cloning, are underlined. (B) Am-
plification, cloning, and expres-
sion strategy. The expression
vector pVC38H is similar to
pVC387 (18) but contains Nde I
and HindIl cloning sites. PE40
is a modified form of PE that
contains only the translocation
and ADP ribosylating domains.
E. coli BL21 (ADE3) carrying the
plasmids shown in this scheme
express recombinant proteins
upon isopropyl 83-D-thiogalacto-
pyranoside induction (20). The
linker peptide sequence is
shown in pOVB3 154-2 and its
last two codons constitute an Sal
I site. Amp, /3-lactamase gene;
B, BamHI; E, EcoRI; H, Hin-
dIII; N, Nde I; S, Sal I; X,
Xba I.
OVB3 (Fv)-PE bound to OVCAR3 cells (Fig. 2C), and this
could be blocked by competition with excess OVB3, indicating
the specificity of the binding (Fig. 2D).
As shown in Fig. 5, OVB3 (Fv)-PE inhibited protein
synthesis in OVCAR3 cells in a dose-dependent manner with
an ID50 of 4 ng/ml. Its cytotoxic effect was blocked by
competition with excess OVB3 but not with a control anti-
body, anti-Tac, demonstrating that the cytotoxic effect was
specific. OVB3 (Fv)-PE did not specifically kill HUT 102
cells or Swiss 3T3 cells that do not react with OVB3 as
demonstrated by the fact that there was no protection by
excess OVB3 (50 tkg/ml) (Table 2). OVB3-PE, the chemical
conjugate between OVB3 and PE, was only 4-fold more
active on OVCAR-3 cells than OVB3 (Fv)-PE but more
specific because it had less activity against antigen-negative
cells (HUT 102 and Swiss 3T3) and was better competed by
OVB3 on OVCAR3 cells (Table 2). The chemical conjugation
reaction modifies lysine residues important for the binding of
PE to the PE receptor (27), whereas in the recombinant
molecule only the N-terminal amino group is modified.
Appropriate mutations in domain I could decrease the non-
specific cytotoxic activity of OVB3 (Fv)-PE.
DISCUSSION
We have described a simple and efficient strategy to clone
and express in E. coli genes encoding the VL and VH ofmAbs.
The variable-region genes are cloned as a functional single-
chain antibody toxin fusion protein whose ability to bind to
target cells can be readily assessed either by fluorescence
(Fig. 2) or by cytotoxic activity (Fig. 4). The strategy takes
advantage of the fact that the 5' ends of the genes encoding
mature VL and VH are very much conserved; similarly, at the
3' end the J-region sequences are also conserved. Primers
based on these sequences can be designed for PCR to amplify
VL and VH sequences starting from RNA, and restriction
sites can be created for cloning (12). Computer analysis of
published VL and VH sequences shows that there are many
different restriction sites that are rarely present in antibody
genes and would be useful for cloning these fragments (Table
1). We selected Nde I and HindIII sites for cloning because
these are present in our toxin expression vector, but based on
Table 1 it should be possible to engineer other cloning sites
not found in antibodies to clone fragments into either pro-
karyotic or eukaryotic expression vectors to make chimeric
antibodies. In the case of OVB3, the N-terminal amino acid
sequences of the variable regions were available and the
primers were based on these sequences. However, if protein
sequence data were not available, it is possible to use primers
with degenerate codons to clone variable-region genes (12,
14). Some of the sites used previously (12) for cloning VL and
VH genes may not be generally useful because of the high
probability of the sites being present in the VL or VH regions
of many antibodies (Table 1).
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FIG. 2. Immunofluorescence detection of binding of OVB3 (Fv)-
PE40 and OVB3 (Fv)-PE in OVCAR3 cells. OVCAR3 cells were
incubated at 4°C either with crude extracts of recombinant OVB3
(Fv)-PE40 alone (A) or in the presence of excess OVB3 (B), or with
purified recombinant OVB3 (Fv)-PE alone (C) or in the presence of
excess OVB3 (D). Surface-bound proteins were detected with rabbit
polyclonal antiserum against PE, followed by rhodamine-conjugated
goat anti-rabbit immunoglobulin.
The nucleotide sequence of two separate clones of mAb
OVB3 were identical except that OVB158-2 did not have an
NdeI
1 (L) 10 20
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FIG. 3. Nucleotide sequence ofOVB3 light and heavy chains. The
sequence is shown as a single chain joined together with a linker. The
top line shows amino acids in the single-letter code. Complementarity-
determining regions (CDRs) and linker amino acids are boxed. 1(L),
Beginning of the light chain; 1(H), beginning of the heavy chain.
Cloning sites created by PCR are underlined. Sequences encoding
PE40 (amino acids 253-613 ofPE), which are present after the HindIII
site, are not shown. Boldface amino acids were determined by
N-terminal amino acid sequencing of the OVB3 antibody. Arrow,
amino acids encoded within the VL-5' and VH-5' primers.
FIG. 4. SDS/PAGE of
OVB3 (Fv)-PE at various stages
of purification. Proteins were
separated in 10% acrylamide
gels and stained with Coomassie
blue. Lanes: A, total cell pellet;
B, pool after Mono Q column; C,
pool after TSK250 column.
Sizes of protein standards are
shown in kDa.
Nde I site due to the loss of one base (C) from the site. We
do not know whether this occurred during PCR or in a
subsequent step of cloning. The strategy described here
would not determine the real 5' and 3' sequences of VL and
VH as these are dictated by the primers. However, work of
Winter and his colleagues (24-26) have shown that trans-
planting the complementarity-determining regions from one
antibody to another maintains the specificity of the antibody.
Thus, framework regions, which may be slightly altered
because of the choice of primers, are unlikely to affect the
specificity of the reconstructed antibody or immunotoxin.
Expression of cloned variable domains as fusion proteins
with a toxin such as PE is very advantageous, as the proteins
from these clones can be directly tested for cytotoxicity or
binding on the target cell line bearing the appropriate antigen.
Depending on the nature ofantigen, vectors capable ofmaking
fusion proteins with PE40 or PE can be used. The current
immunotoxin was constructed initially by using aPE clone that
encodes a form of PE (PE40) that does not contain domain I.
When this fusion protein is bound to its antigen, which is
poorly internalized, cell killing is minimal. However, the
binding of OVB3 (Fv)-PE40 to antigen-bearing cells could be
detected by using antibodies to PE, and immunofluorescence
was used to identify clones binding to OVCAR3 cells. The
PE40 vectors would also be useful for distinguishing between
antibodies that bind to antigens that are internalized and to
those that are not. A chimeric toxin of the former type is
anti-Tac (Fv)-PE40 (8). If the antigen is not internalized or is
poorly internalized, a fusion protein with PE may be useful
because the binding of domain I of PE promotes internaliza-
tion. It should also be possible to detect the antibody-toxin
fusion protein by ELISA if the antigen is coated on a plate or
nitrocellulose.
._
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.1 10 100 1000
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FIG. 5. Cytotoxicity of OVB3 (Fv)-PE on OVCAR3 cells. Var-
ious dilutions of OVB3 (Fv)-PE were added to OVCAR3 cells and
incubated for 16 hr. Cytotoxicity was measured by determining
[3H]leucine incorporation and results are expressed as percent of
control with no toxin added. *, OVB3 (Fv)-PE alone; o, OVB3
(Fv)-PE + anti-Tac (50 ,.g/ml); A, OVB3 (Fv)-PE + OVB3 (50
Ag/ml).
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Table 2. Cytotoxicity of OVB3 (Fv)-PE and OVB3-PE on
various cell lines
ID50, ng/ml
OVB3 (Fv)-PE OVB3-PE
Cell line - OVB3 + OVB3 - OVB3 + OVB3
OVCAR3 4 46 1 1000
HUT 102 20 14 1200 1200
Swiss 3T3 7 8 53 50
Cytotoxicity was determined by assaying inhibition of protein
synthesis as measured by the incorporation of [3H]leucine in the
trichloroacetic acid-precipitable fraction. ID50 is the concentration of
the protein required to inhibit protein synthesis by 50% as compared
to control, in which no toxin was added. + OVB3, Addition of mAb
OVB3 at 50 ,ug/ml just prior to the addition of toxin. OVB3-PE is a
chemical conjugate.
Previous strategies for cloning variable-region genes of
antibodies from RNA have had to reassemble the individual
genes into a functional antibody by subcloning and expres-
sion in mammalian vectors (12). This approach is slow and
tedious and requires several subcloning steps and the growth
of antibody-producing cells in tissue culture. Using the
method described here, from total RNA it is possible to
isolate functional antibody genes in 1-2 weeks. Because the
chimeric antibody-toxin molecule is made in E. coli, it is
possible to make large amounts of the reagent for various
types of biochemical and biological studies (8).
The choice of the linker used to make the single-chain
immunotoxin may be very important. We have previously
reported a very active immunotoxin, anti-Tac (Fv)-PE40,
that contained a linker composed of glycine and serine
residues (8). The linker used in the current construction
contains several charged amino acids (Fig. 1B), some of
which were introduced for convenience of cloning.
It has been previously pointed out that it should be possible
to directly clone functional antibody genes from the spleens
of immunized mice or from B cells of humans by using
appropriate primers and PCR-based gene amplification (12,
14). The ability to clone such sequences as functional single-
chain antibodies whose activity can be readily detected by
fluorescence or in cytotoxic assays should make this goal
more readily achievable.
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